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Abstract
 
The development of T cells in the thymus is coordinated by cell-specific gene expression pro-
grams that involve multiple transcription factors and signaling pathways. Here, we show that
the p38 mitogen-activated protein (MAP) kinase signaling pathway is strictly regulated during
the differentiation of CD4
 
2
 
CD8
 
2
 
 thymocytes. Persistent activation of p38 MAP kinase blocks
fetal thymocyte development at the CD25
 
1
 
CD44
 
2
 
 stage in vivo, and results in the lack of T
cells in the peripheral immune system of adult mice. Inactivation of p38 MAP kinase is re-
quired for further differentiation of these cells into CD4
 
1
 
CD8
 
1
 
 thymocytes. The arrest of cell
cycle in mitosis is partially responsible for the blockade of differentiation. Therefore, the p38
MAP kinase pathway is a critical regulatory element of differentiation and proliferation during
the early stages of in vivo thymocyte development.
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Introduction
 
The generation of T cells in the thymus is mediated by a
complex biological mechanism that combines differentia-
tion, proliferation, death, selection, and lineage commit-
ment. These processes require TCR signals together with
signals delivered by cell–cell interactions and soluble factors
provided by the thymic environment. Stem cells seed the
thymus and differentiate into immature CD4
 
2
 
CD8
 
2
 
 dou-
ble negative (DN)
 
1
 
 thymocytes, which represent a minor
population (3–5%) in the adult thymus. DN thymocytes
express CD8 on the cell surface first, progressively acquire
the expression of CD4 (CD8
 
1
 
CD4
 
low
 
), and become CD4
 
1
 
CD8
 
1
 
 thymocytes. The immature CD8
 
1
 
CD4
 
low
 
 population
is clearly detected during fetal thymocyte development (em-
bryonic days E16–18), but is almost undetectable in the adult
thymus. Based on the expression of the cell surface markers
CD25 (IL-2 receptor 
 
a
 
 chain), CD44, and c-Kit, the differ-
entiation of DN thymocytes follows the sequence c-Kit
 
1
 
CD25
 
2
 
CD44
 
1
 
 (most immature), c-Kit
 
1
 
CD25
 
1
 
CD44
 
1
 
,
c-Kit
 
2
 
CD25
 
1
 
CD44
 
2
 
, and c-Kit
 
2
 
 CD25
 
2
 
CD44
 
2
 
 (for a
review, see reference 1). Downmodulation of CD25 from
the cell surface is associated with the expression of the pre-
TCR, which is formed by the association of the TCR 
 
b
 
chain with gp33/pre-T
 
a
 
. Signals mediated by the pre-TCR
complex induce the differentiation of DN thymocytes into
CD4
 
1
 
CD8
 
1
 
 double positive (DP) cells. DP cells undergo
both positive and negative selection, which involve signals
delivered by the interaction of the TCR with the corre-
sponding MHC, and additional signals provided by stromal
cells. As a result of these processes, and the downmodulation
of either CD4 or CD8 coreceptors, DP thymocytes differen-
tiate into mature single CD4
 
1
 
 or CD8
 
1
 
 thymocytes.
Impairments of the appropriate signals occurring during
the generation of T cells in the thymus can lead to immune
disorders. Defective deletion of autoreactive T cells in the
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thymus during negative selection results in the presence of
these cells in the peripheral immune system and can lead to
autoimmune diseases. The failure to successfully undergo
positive selection may be reflected by the absence of anti-
gen-specific T cells in the peripheral immune system. More
importantly, impairment of early DN thymocyte develop-
ment can result in a severe T cell immunodeficiency.
Thymocyte development is coordinated by cell-specific
gene expression programs. Several transcription factors and
signaling pathways provide critical checkpoints (for reviews,
see references 1–4). The mitogen-activated protein (MAP)
kinase signaling cascades have been implicated in cell growth,
differentiation, and death (5). This family of kinases also
plays an important role in thymocyte selection. The extra-
cellular signal regulatory kinase (ERK) MAP kinase signal-
ing pathway is required for positive selection and lineage
commitment, but is not necessary for negative selection (6).
c-Jun NH
 
2
 
-terminal kinase (JNK) and p38 MAP kinase
pathways have been implicated in negative selection of DP
thymocytes (7, 8). ERK activation is also required for dif-
ferentiation of DN into DP thymocytes (9). The roles of JNK
and p38 MAP kinases in early thymocyte differentiation
have not yet been determined.
p38 MAP kinase is activated by phosphorylation on Thr
and Tyr residues by the MAP kinase kinases MKK3, MKK4,
and MKK6 (10–13). Intrathymic signals appear to activate
the p38 MAP kinase pathway in thymocytes from recom-
bination-activating gene (RAG)-2–deficient mice (14), sug-
gesting that this pathway could also play a role in early thy-
mocyte development. Previous studies have established that
the p38 MAP kinase pathway can be regulated by several
cytokines, including TNF-
 
a
 
, IL-1, CSF-1, GM-CSF, IL-3,
IL-2, and IL-7 (15–20). Some of these cytokines, notably
TNF-
 
a
 
, IL-1, and IL-7, are involved in differentiation and
cell expansion of DN thymocytes. Here, we show that the
p38 MAP kinase pathway is strictly regulated during differ-
entiation of DN thymocytes. The persistent activation of
p38 MAP kinase in vivo arrests cell cycle progression and
differentiation of immature fetal thymocytes at the CD8
 
1
 
CD4
 
low
 
CD25
 
1
 
CD44
 
2
 
 stage, leading to a lack of T cells in
the peripheral immune system. Therefore, the p38 MAP
kinase plays an essential regulatory role in early thymocyte
development.
 
Materials and Methods
 
Generation of Transgenic Mice.
 
The constitutively activated MKK6
cDNA was generated by replacing Ser
 
207
 
 and Thr
 
211
 
 by Glu (MKK6
[Glu]) (13). The dn p38 MAP kinase mutant was generated by
replacing Thr
 
180
 
 and Tyr
 
182
 
 by Ala and Phe, respectively (16). The
Flag epitope tag was inserted between codons 1 and 2 of the MKK6
and p38 cDNAs, which were subcloned downstream of the
proximal 
 
lck
 
 MKK6(Glu) promoter (6, 21, 22). The DNA frag-
ments containing the proximal 
 
lck
 
 promoter, the MKK6(Glu)
gene, and the 
 
b
 
-globin intron and polyadenylation signals, or the
proximal 
 
lck
 
 promoter, dn p38 gene, and the human growth hor-
mone intron and polyadenylation sequence were injected into
fertilized (C57BL/6 
 
3
 
 C
 
3
 
H)F2 eggs. Transgenic mice were gen-
erated as described previously (23). Transgene expression was an-
alyzed by slot blot using a 500-bp fragment of the proximal 
 
lck
 
promoter (MKK6[Glu]) or a 500-bp fragment from the human
growth hormone sequence (dn p38). The founders were back-
crossed into B10.BR mice (The Jackson Laboratory) to establish
stable transgenic lines.
 
Flow Cytometry Analysis.
 
The distribution of populations in
the thymus, spleen, and lymph nodes was examined by cell sur-
face staining and flow cytometry (EPICS; Coulter). The following
antibodies and conjugates were used: PE-conjugated anti-CD4
mAb, a red
 
613
 
-conjugated anti-CD8 mAb, red
 
613
 
-streptavidin
(GIBCO BRL); FITC-conjugated anti-CD25, biotinylated anti-
TCR (H57), biotinylated anti-CD69, biotinylated anti–heat sta-
ble antigen (HSA) or anti-CD25, red
 
670
 
-streptavidin (PharMin-
gen); PE–anti-CD44 (Caltag); and Quantum red–anti-CD4 and
Quantum red–anti-CD8 (Sigma Chemical Co.). Isolation of
CD8
 
1
 
CD4
 
low
 
CD25
 
1
 
CD44
 
2
 
 and CD8
 
1
 
CD4
 
low
 
CD25
 
2
 
CD44
 
2
 
populations was performed by staining with the corresponding
mAbs and cell sorting (EPICS; Coulter). Staining was performed
in the presence of Fc Block (PharMingen) in all conditions.
Intracellular staining for cyclin A and p27 was performed as
described (24). The cells were stained for cell surface expression
of CD4 and CD8, fixed with 1% paraformaldehyde, and permea-
bilized with cold 0.1% (wt/vol) saponin, 1% bovine serum albu-
min (BSA) fraction V (Sigma Chemical Co.) in PBS. The cells
were incubated sequentially with either a rabbit anti–mouse cy-
clin A or goat anti–mouse p27 (Santa Cruz Biotechnology), fol-
lowed by either FITC-conjugated anti–rabbit IgG or FITC-con-
jugated anti–goat IgG, respectively. To examine intracellular staining
for TCR 
 
b
 
 chain, the thymocytes were stained for surface CD4,
CD8, CD25, and CD44 and fixed with 1% (vol/vol) methanol-
free formaldehyde in PBS for 15 min at 4
 
8
 
C. Fixed thymocytes
were then permeabilized with cold 0.03% (wt/vol) saponin in
PBS/1% BSA and stained using an FITC-conjugated anti–TCR-
 
b
 
mAb (H57; PharMingen) or an FITC–hamster Ig as an isotype
control. Both cell surface and intracellular staining were per-
formed in the presence of Fc Block (PharMingen).
 
Histological Analysis.
 
Tissues were fixed in 1% paraformalde-
hyde, embedded in TissueTek, sectioned, and stained with he-
matoxylin and eosin. Freshly isolated or treated thymocytes
were cytospun, fixed in methanol for 7 min, and stained with
Giemsa.
 
Cell Cycle Analysis.
 
Total thymocytes (10
 
6
 
 cells) were resus-
pended in low salt staining solution (3 g/ml polyethylene glycol
PEG 8000, 50 
 
m
 
g/ml propidium iodide, 180 U/ml RNase A, 0.1%
Triton X-100, 4 mM sodium citrate) and incubated at 4
 
8
 
C for 30
min. An equal volume of high salt solution (3 g/ml polyethylene
glycol PEG 8000, 50 
 
m
 
g/ml propidium iodide, 180 U/ml RNase A,
0.1% Triton X-100, 400 mM sodium chloride) was added. Propid-
ium iodide incorporation was analyzed by flow cytometry.
 
Bromodeoxyuridine Staining.
 
Bromodeoxyuridine (BrdU) incor-
poration was examined as described previously (25). Mice were
administered three intraperitoneal injections of 1 mg of BrdU in
PBS at 4-h intervals on day 1. On day 2, an additional intraperi-
toneal injection was administered 1 h before killing the mouse.
Thymocytes were fixed in 70% ethanol, washed with PBS, fixed
again in 1% paraformaldehyde, washed, and incubated for 30 min
at 37
 
8
 
C in 0.15 M NaCl, 4.2 mM MgCl
 
2
 
, and 100 U/ml DNase.
Cells were then stained with FITC-conjugated anti-BrdU (Bec-
ton Dickinson) at room temperature, washed, and analyzed by
flow cytometry.
 
TUNEL Assay.
 
To determine incidence of apoptosis, total
thymocytes were fixed in 1% paraformaldehyde, permeabilized in 
323
 
Diehl et al.
 
70% ethanol, and assayed for apoptosis via terminal deoxynucleo-
tidyl transferase–mediated FITC-dUTP nick end labeling (TUNEL),
as recommended by the manufacturer (PharMingen).
 
p38 and JNK MAP Kinase Assays.
 
Cells were lysed with buffer A
(20 mM Tris, pH 7.5, 10% glycerol, 1% Triton X-100, 0.137 M
NaCl, 25 mM 
 
b
 
-glycerophosphate, 2 mM EDTA, 0.5 mM
dithiothreitol, 1 mM sodium orthovanadate, 2 mM sodium pyro-
phosphate, 10 
 
m
 
g/ml leupeptin, 1 mM PMSF) as described (26, 27).
Endogenous p38 MAP kinase and JNK were immunoprecipi-
tated using anti-p38 polyclonal antibody (16) or anti-JNK poly-
clonal antibody (Santa Cruz Biotechnology), respectively. These
antibodies were prebound to protein A–sepharose. The immuno-
precipitates were washed twice with buffer A and twice with ki-
nase buffer (25 mM Hepes, pH 7.4, 25 mM 
 
b
 
-glycerophosphate,
25 mM magnesium chloride, 0.5 mM dithiothreitol, 0.1 mM so-
dium orthovanadate). The protein kinase reactions were initiated
by addition of 1 
 
m
 
g of recombinant substrate protein (glutathione
 
S
 
-transferase [GST]-ATF2 for p38 and GST-c-Jun for JNK) and
50 
 
m
 
M [
 
g
 
-
 
32
 
P]ATP (10 Ci/mmol). The reactions were termi-
nated after 30 min at 30
 
8
 
C by addition of Laemmli sample buffer.
Phosphorylation of the substrate protein was examined after
SDS-PAGE by autoradiography and PhosphorImager analysis
(Molecular Dynamics).
p38 MAP kinase activation was also determined by intracellu-
lar staining. Total thymocytes were stained with anti-CD4, anti-
CD8, anti-CD25, and anti-CD44 mAbs, in the presence of Fc
Block (PharMingen). Stained cells were fixed for 20 min in 4%
paraformaldehyde, and incubated in permeabilization buffer (1%
FCS, 0.1% saponin/PBS) in the presence of an FITC–antiphos-
pho-p38 MAP kinase mAb (Santa Cruz Biotechnology). The
cells were examined by flow cytometry.
 
Western Blot Analysis.
 
Proteins were fractionated by SDS-PAGE,
electrophoretically transferred to an Immobilon-P membrane
(Millipore), and probed with an anti-p38 polyclonal antibody
(Santa Cruz Biotechnology) to detect endogenous p38 MAP ki-
nase, or anti-Flag mAb (Sigma Chemical Co.) to detect MKK6
(Glu). Immunocomplexes were detected using chemiluminescence
(LumiGLO™; Kirkegaard & Perry).
 
Results
 
Increased p38 MAP Kinase Activity in Immature Thymocytes.
 
To investigate the role of the p38 MAP kinase pathway in
thymocyte development, we first examined p38 MAP ki-
nase activity in freshly isolated DN, DP, and mature CD4
 
1
 
thymocytes from wild-type mice. Consistent with a previ-
ous report (14), we found that p38 MAP kinase was highly
activated in DN thymocytes (Fig. 1 A). The level of p38
MAP kinase activity in DP thymocytes was lower than the
activity found in DN thymocytes. Only low levels of p38
MAP kinase activity were detected in mature CD4
 
1
 
 thy-
mocytes (Fig. 1 A). These results suggested that inactivation
of p38 MAP kinase may be important for thymocyte matu-
ration. To address this possibility, we have developed a
mouse model in which p38 MAP kinase is persistently acti-
vated during early thymocyte development.
 
Abnormal Thymocyte Cellularity in the MKK6(Glu) Trans-
genic Mice.
 
MKK6 is an upstream activator of p38 MAP
kinase (11–13) and does not activate other MAP kinase
family members such as JNK or ERK. MKK6 is activated
by dual phosphorylation within subdomain VIII. The re-
placement of Ser
 
207
 
 and Thr
 
211
 
 with Glu generates an acti-
vated MKK6 (MKK6[Glu]) that is able to phosphorylate
p38 MAP kinase in the absence of prior stimulation (13).
Here, we generated transgenic mice that express MKK6(Glu)
in thymocytes using the proximal 
 
lck
 
 promoter, which
drives a high level of expression in all thymocyte popula-
tions. Thus, thymocytes in these mice maintain p38 MAP
kinase constitutively activated.
We examined the expression of MKK6(Glu) protein in
three transgenic mouse lines by immunoblot analysis using
an antibody that recognizes the Flag epitope incorporated
into the transgene. The MKK6(Glu) was expressed in thy-
mocytes from all three transgenic mouse lines. The level of
expression obtained in line 6 was dramatically higher (10–
15-fold) than the other two lines (Fig. 1 B). A low level of
transgene expression was also observed in the spleen (Fig. 1 B).
The expression of constitutively activated MKK6 resulted
in increased p38 MAP kinase activity in thymocytes from
the MKK(Glu) transgenic mice (Fig. 1 C), but did not af-
fect JNK activity (Fig. 1 C), demonstrating the specific ef-
fect of MKK6 on the p38 MAP kinase pathway in vivo.
The thymus from 2–3-mo-old mice exhibited reduced cel-
lularity in each of three transgenic lines compared with neg-
ative littermate control mice (Fig. 1 D). Consistent with
the level of MKK6(Glu) expression and p38 MAP kinase
activity (Fig. 1, B and C), the most dramatic effect was ob-
served in transgenic mice from line 6 (Fig. 1 D).
Interestingly, despite the reduced cell number, the size of
thymi from 2–3-mo-old MKK6(Glu) transgenic mice (line
6) was slightly larger than thymi of negative littermate con-
trol mice (Fig. 1 E). The weights of thymi from 2–3-mo-
old MKK6(Glu) transgenic mice were approximately two-
fold greater than those of age-matched negative littermate
controls (Fig. 1 F), although the number of thymocytes was
reduced (Fig. 1 G). The difference in thymus size between
transgenic and control mice increased with age. At 5–5.5
mo, the thymi of the MKK6(Glu) transgenic mice were
dramatically enlarged (Fig. 1 E). The weight of the thymi
(Fig. 1 F) and the number of thymocytes (Fig. 1 G) were, re-
spectively, 8–10-fold and 3-fold greater than the weight
and the number of thymocytes in age-matched negative lit-
termate control mice. The MKK6(Glu) transgenic mice
(line 6) died between 5.5 and 6 mo of age. 1 or 2 wk be-
fore death, the mice exhibited signs of respiratory distress
characterized by a reduced respiratory rate and gasping.
Death ensued, apparently due to either compression of the
trachea or extinction of lung expansion (Fig. 1 E, right).
Death did not appear to be secondary to extrinsic compression
of the heart, as there was no evidence of hepatic congestion,
ascites, or peripheral edema characteristic of heart failure.
 
Absence of T Cells in the Peripheral Lymphoid Organs of the
MKK6(Glu) Transgenic Mice.
 
In contrast to the dramati-
cally enlarged thymus, the spleen and lymph nodes of the
MKK6(Glu) transgenic mice were significantly smaller
(Fig. 2 A). Very few cells could be obtained from lymph
nodes from the MKK6(Glu) transgenic mice (100-fold re-
duction; Fig. 2 B). The number of cells in the spleen from
these mice was also significantly reduced (Fig. 2 B). Histo- 
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Figure 1. Progressive enlargement of the thymus in the MKK6(Glu) transgenic mice. (A) p38 MAP kinase activity in thymocyte populations from
wild-type mice. Whole cell extracts (4 3 105) of freshly isolated total thymocytes (T.T), DN, DP, and mature single CD41 thymocytes from wild-type
mice were assayed for p38 MAP kinase activity using the substrate GST-ATF2. (B) Expression of MKK6(Glu) in the MKK6(Glu) transgenic mice. The
expression of endogenous p38 MAP kinase and the MKK6(Glu) transgene (MKK6) was analyzed in thymocytes and spleen cells from negative littermate
control mice (NLC) and mice from three different MKK6(Glu) transgenic (Tg1) lines (lines 45, 3, and 6) by Western blot analysis. Blots were probed
with either an anti-Flag antibody (MKK6) or an anti-p38 MAP kinase polyclonal antibody (p38). (C) Activation of p38 MAP kinase by the expression of
MKK6(Glu) in thymocytes. Total thymocytes (5 3 105 cells) from MKK6(Glu) transgenic mice and negative littermate control mice were lysed, and
whole extracts were assayed for p38 activity using the substrate GST-ATF2 or for JNK activity using the substrate GST-c-Jun. (D) Diminished thy-
mocyte number in the MKK6(Glu) transgenic mice. Data represent the percentage of the total number of cells in the thymus from the MKK6(Glu) trans-
genic mice from different lines compared with the total number of thymocytes in negative littermate control mice. (E) Enlarged thymus in the
MKK6(Glu) transgenic mice. Thymi from 3- and 5.5-mo-old (3 m and 5 m, respectively) negative littermate control and MKK6(Glu) transgenic (line 6)
mice (left two panels). Thymus (thick arrow) and lungs (thin arrow) from 5.5-mo-old (5 m) negative littermate control and MKK6(Glu) transgenic mice
(right two panels). (F) Weight of thymi from 2.5–3.5- and 4.5–5.5-mo-old (3 m and 5 m, respectively) negative littermate control and MKK6(Glu) trans-
genic mice. Values represent average weight (n 5 4). (G) Progressive accumulation of thymocytes in the MKK6(Glu) transgenic mice. Values represent the
average (n 5 4) of the number of total thymocytes in 3- and 5-mo-old negative littermate control and MKK6(Glu) transgenic mice.325 Diehl et al.
logical analysis confirmed that the spleen from the MKK6
(Glu) transgenic mice contained only a few cells in the T
cell zone, but B cell zones were not affected (Fig. 2 C).
Lymph nodes from the MKK6(Glu) mice contained stro-
mal cells, but were virtually devoid of lymphocytes (Fig.
2 C). Cell surface staining and analysis by flow cytometry
demonstrated that CD41 and CD81 T cells were almost
absent in spleen and lymph nodes from the MKK6(Glu)
transgenic mice (Fig. 2 D). B cells were the major popula-
tion present in these organs from the MKK6(Glu) trans-
genic mice (data not shown). These results indicated that
the expression of constitutively activated MKK6 in thy-
mocytes caused a T lymphocyte immunodeficiency.
Immature Thymocyte Development Arrested by the Persistent
Activation of p38 MAP Kinase. The absence of T cells in
the peripheral immune organs (Fig. 2) and the progressive
enlargement of the thymus (Fig. 1 E) suggested an impair-
ment of thymocyte development. Histological analysis sup-
ported this hypothesis (Fig. 3 A). Thymi from the MKK6
(Glu) transgenic mice contained uniform cortical areas (im-
mature thymocytes) and lacked defined medulla (mature
thymocytes) (Fig. 3 A), indicating that the expression of
MKK6(Glu) resulted in an accumulation of immature thy-
mocytes. To determine the specific stage of differentiation
of the thymocytes, we examined the expression of CD4 and
CD8 cell surface markers. The DP population defined by
a high cell surface expression of both CD4 and CD8
(CD81CD41) was not detected in the MKK6(Glu) trans-
genic mice (Fig. 3 B). Surprisingly, most thymocytes from
the MKK6(Glu) transgenic mice were CD81CD4low (Fig.
3 B). The immature CD81CD4low population is a transient
stage clearly identified during fetal thymic differentiation of
DN thymocytes into DP thymocytes, although very few
CD81CD4low cells can be detected in adult thymus in wild-
type mice. These results suggest that the expression of
MKK6(Glu) may arrest immature thymocyte differentiation.
Figure 2. Expression of activated MKK6 in thymocytes results in the lack of T cells in peripheral lymphoid organs. (A) Small lymph nodes and spleen
in the MKK6(Glu) transgenic mice. Lymph nodes (LN) and spleen from 5.5-mo-old negative littermate control (NLC) and MKK6(Glu) transgenic
(Tg1) mice. (B) Decreased numbers of cells in lymph nodes and spleen. Values represent the average (n 5 4) of the number of total lymph node and
spleen cells in negative littermate control and MKK6(Glu) transgenic (line 6) mice (4–5.5 mo of age). (C) Lack of T cell area in peripheral lymphoid or-
gans. Hematoxylin and eosin–stained tissue sections from spleen and lymph nodes of negative littermate control and MKK6(Glu) transgenic mice. B cell
(B) and T cell (T) areas are labeled. (D) Lack of CD41 and CD81 T cells. Cells from lymph nodes and spleen from negative littermate control or
MKK6(Glu) transgenic mice were isolated, stained for CD4 and CD8, and analyzed by flow cytometry. Numbers represent the percentage of cells in
each quadrant.326 Activation of p38 MAP Kinase Arrests Thymocyte Development
Figure 3. Expression of activated MKK6 blocks dif-
ferentiation of immature thymocytes. (A) Lack of thy-
mic medulla in the MKK6(Glu) transgenic mice. He-
matoxylin and eosin–stained thymus sections from
negative littermate control (NLC) and MKK6(Glu)
transgenic (Tg1) mice. (B) CD81CD4low thymocytes
constitute the major population in the thymus from the
MKK6(Glu) transgenic mice. Total thymocytes from
negative littermate control and the MMK6(Glu) trans-
genic mice were stained for CD4 and CD8 and ana-
lyzed by flow cytometry. (C) CD81CD4lowCD251
CD442 thymocytes constitute the major thymocyte
population in the MKK6(Glu) transgenic mice. Total
thymocytes from control and the MKK6(Glu) trans-
genic mice were stained for CD4, CD8, CD25, and
CD44. CD25 and CD44 expression was examined in
each gated thymocyte population. Numbers represent
the percentage of cells in each quadrant. (D) Expression
of thymocyte maturation markers on MKK6(Glu) thy-
mocytes. Histograms represent the cell surface expres-
sion of TCR-b, CD69, and HSA on CD42CD82 DN, CD41CD81 DP, and CD81 single-positive thymocytes from negative littermate control mice;
CD81CD4low thymocytes from the MKK6(Glu) transgenic mice; and CD81CD4low fetal thymocytes from day 16 negative littermate control embryos
(Fetal NLC) analyzed by flow cytometry. (E) Expression of activated MKK6 blocks fetal thymocyte development. Fetal thymi were isolated from neg-
ative littermate control and the MKK6(Glu) transgenic embryos at E15, E16, or E19. Total fetal thymocytes were stained for CD4 and CD8 and analyzed
by flow cytometry. (F) Elevated p38 MAP kinase activity in CD251CD442 thymocytes. Fetal thymocytes from wild-type E18 embryos were isolated,
pooled, and stained for CD4, CD8, CD25, and CD44. CD81CD4lowCD251CD442 and CD252CD442 populations were purified by cell sorting, lysed,
and assayed for p38 MAP kinase activity using GST-ATF2 as a substrate as described in the legend to Fig. 1 B.327 Diehl et al.
The expression of CD25 and CD44 characterizes the
specific differentiation stages within the DN population
(Fig. 3 C). The expression of CD25 during thymocyte de-
velopment is restricted to this immature stage. Interestingly,
CD81CD4low thymocytes from the MKK6(Glu) transgenic
mice expressed high levels of CD25, but did not express
CD44 (Fig. 3 C). Thus, the expression of activated MKK6
blocked thymocyte differentiation and led to an accumula-
tion of immature CD81CD4lowCD251CD442 thymocytes.
The high level of HSA characteristic of immature cells and
the lack of expression of CD69 (mature thymocytes) (Fig.
3 D) confirm the immature phenotype of the thymocytes
in the MKK6(Glu) transgenic mice. The high level of HSA
present on thymocytes from the MKK6(Glu) transgenic
mice was comparable to the level expressed in E16 fetal
thymocytes from control mice (Fig. 3 D), supporting the
immature phenotype of the thymocytes from the MKK6
(Glu) transgenic mice. Low but significant levels of TCR-b
expression were detected in the CD81CD4low population
from the MKK6(Glu) transgenic mice (Fig. 3 D), suggest-
ing that the pre-TCR could already be present on these
immature thymocytes.
To further demonstrate that activated MKK6 arrested
thymocyte development at an early stage, we examined in
vivo fetal thymic development during embryogenesis.
CD81CD4low thymocytes constituted the predominant pop-
ulation at E16–17, whereas CD81CD4low thymocytes had
already differentiated into DP thymocytes in E19 wild-type
embryos (Fig. 3 E). In contrast, at E19 only CD81CD4low
thymocytes were found in the MKK6(Glu) embryos (Fig.
3 E). In control mice, the differentiation of CD81CD4low
fetal thymocytes into DP fetal thymocytes is associated with
a remarkable increase in cell number (z10-fold per day).
Consistent with the arrest at the CD81CD4low stage, the
number of fetal thymocytes at E19 was dramatically lower
(three- to fourfold) in the MKK6(Glu) embryos compared
with the number found in control fetal thymi (data not
shown). The number of total thymocytes in the MKK6
(Glu) transgenic mice was consistently lower than the
number of thymocytes in control mice during the first 2–3
mo of age. These results indicated that the early arrest of thy-
mocyte differentiation at the CD81CD4lowCD251CD442
stage in the MKK6(Glu) transgenic mice was associated
with an inhibition of the expansion of these immature cells.
The increased number of thymocytes observed in MKK6
(Glu) transgenic mice by 5–6 mo of age may be the result
of the continuous entry of new cohorts of bone marrow–
derived precursor thymocytes and their limited expansion
before the CD251CD442 stage.
Our data demonstrated that a persistent activation of p38
MAP kinase arrested the differentiation and expansion of im-
mature CD81CD4lowCD251CD442 thymocytes and sug-
gested that p38 MAP kinase must be inactivated during the
transition from the CD251CD442 to the CD252CD442
stage. To test this hypothesis, we examined p38 MAP ki-
nase activity in CD81CD4lowCD251CD442 and CD81
CD4lowCD252CD442 thymocytes from wild-type mice.
p38 MAP kinase activity was substantially higher in the
CD251CD442 subpopulation compared with the activity
found in the CD252CD442 cells (Fig. 3 F). Therefore, p38
MAP kinase was inactivated during the differentiation of
CD251CD442 into CD252CD442 thymocytes, and the per-
sistent activation of this pathway in the MKK6(Glu) trans-
genic mice prevented this differentiation step.
Inhibition of Mitotic Progression of CD251CD442 Thymo-
cytes by Activation of p38 MAP Kinase. Two subpopulations,
defined by cell size, have been described within the CD251
CD442 immature thymocyte subset (28). The CD251CD442
“E” (expected size) stage, characterized by a small cell size,
precedes the CD251CD442 “L” (large size) stage, charac-
terized by large cells (Fig. 4 A). The CD251CD442 L and
E stages also define cells before (E) or after (L) a successful
b chain rearrangement and expression of the pre-TCR.
Progression from E to L stage is inhibited in mice deficient
in specific components of the pre-TCR (e.g., RAG, pre-
Ta, TCR-b [28]). Histological analysis showed that the cells
present in the thymus from the MKK6(Glu) transgenic
mice were larger than thymocytes from negative littermate
control mice (Fig. 3 A). This size difference was confirmed
by flow cytometry analysis of forward and side scatter (Fig.
4 B), suggesting that thymocytes from the MKK6(Glu)
transgenic mice could be arrested at the L stage. The low
level of cell surface expression of TCR-b detected on
CD81CD4lowCD251CD442 thymocytes from the MKK6
(Glu) transgenic mice (Fig. 3 D) suggested that successful
b chain rearrangement could occur in these cells. To further
demonstrate the presence of functional TCR-b, we ex-
amined the intracellular expression of TCR-b by flow
cytometry. In correlation with previous studies, two popu-
lations of CD251CD442 thymocytes could be clearly distin-
guished based on the intracellular expression of the b chain
in negative littermate control mice (Fig. 4 C). Most CD81
CD4lowCD251CD442 thymocytes from the MKK6 (Glu)
transgenic mice expressed the TCR-b chain, indicating
that b rearrangement had successfully occurred in these
cells (Fig. 4 C). These results indicated that the activation
of p38 MAP kinase resulted in an accumulation of imma-
ture CD251CD442 L thymocytes.
A substantial percentage of the CD251CD442 L thymo-
cytes from wild-type mice has been described to be cycling
cells (28). Therefore, we examined the cell cycle status of
thymocytes from the MKK6(Glu) transgenic mice by mea-
suring DNA content using propidium iodide. Only a small
number of thymocytes was in S and G2/M phases in nega-
tive littermate control mice (Fig. 4 D). In contrast, the
thymi from MKK6(Glu) transgenic mice contained an ele-
vated proportion of cells in the S and G2/M phases and a
low percentage of cells in G0/G1 phase (Fig. 4 D). The in-
creased percentage of thymocytes with .2N DNA content
was observed in both younger (2–3 mo) and older (5–6
mo) MKK6(Glu) transgenic mice.
Despite the elevated number of cells with .2N DNA
content, the total number of thymocytes during fetal devel-
opment through the first 3–4 mo after birth of the MKK6
(Glu) transgenic mice was significantly lower than the num-
ber of thymocytes found in negative littermate control mice.328 Activation of p38 MAP Kinase Arrests Thymocyte Development
Figure 4. Persistent activation of p38 MAP kinase arrests cell cycle in MKK6(Glu)
transgenic mice. (A) Description of the E (expected) and L (large) subsets within the
CD251CD442 subpopulation. (B) Increased thymocyte size in the MKK6(Glu)
transgenic mice. Forward and side scatter of thymocytes from negative littermate
control (NLC) and MKK6(Glu) transgenic (Tg1) mice were determined by flow
cytometry. (C) MKK6(Glu) transgenic thymocytes express TCR b chain protein.
Histograms represent intracellular expression of TCR-b in total thymocytes from the
MKK6(Glu) transgenic mice or DN CD251CD442 thymocytes from negative litter-
mate control mice. Hamster IgG was used as an isotype-matching control. (D) In-
creased number of cells in S/G2/M in the thymus from the MKK6(Glu) transgenic
mice. The cell cycle in total thymocytes from negative littermate control and
MKK6(Glu) transgenic mice was examined by propidium iodide staining and flow
cytometry. Histograms represent the mean fluorescence intensity (MFI) of propi-
dium iodide (PI) incorporation. Numbers represent the percentage of cells in each
phase. (E) Analysis of apoptosis in thymocytes from MKK6(Glu) transgenic mice.
Apoptosis of freshly isolated total thymocytes from negative littermate control and
MKK6(Glu) transgenic mice was examined by TUNEL assay. Histograms represent the mean fluorescence intensity of the incorporation of FITC-
dUTP. Numbers represent the percentage of dUTP1 cells. (F) Normal proliferation rate of MKK6(Glu) thymocytes. In vivo BrdU incorporation in thy-
mocytes from negative littermate control and MKK6(Glu) transgenic mice was determined by intracellular staining using an anti-BrdU mAb. Numbers
represent the percentage of cells that have incorporated BrdU. (G) Accumulation of mitotic thymocytes in the MKK6(Glu) transgenic mice. Total thy-
mocytes from negative littermate control and MKK6(Glu) transgenic mice were cytospun and stained with Giemsa. Two fields of the same preparation
are shown for the transgenic mice. Cells in mitosis (m) or interphase (i) are labeled. (H) Increased expression of cyclin A in the MKK6(Glu) transgenic
thymocytes. p27 and cyclin A expression in thymocytes from negative littermate control and MKK6(Glu) transgenic mice were determined by intracel-
lular staining using unconjugated anti-p27 and anti-cyclin A antisera followed by staining with the corresponding conjugated secondary antibody (red
line, open histograms). Thymocytes stained with the secondary antibody alone are included as a control (gray line, filled histograms). The experiment
shown represent the results from four independent experiments.329 Diehl et al.
These results could be explained by (a) an accelerated entry
of G0/G1 cells into S phase (increased rate of proliferation)
accompanied by an increased cell death, or (b) a partial in-
hibition of cell cycle progression from G2/M into G0/G1
phase and the progressive accumulation of new bone mar-
row–derived precursor thymocytes.
Using TUNEL assay, we examined apoptosis of freshly
isolated thymocytes from negative littermate control and
MKK6(Glu) transgenic mice. No significant numbers of
apoptotic thymocytes were observed in either negative
control or MKK6(Glu) transgenic mice (Fig. 4 E), suggest-
ing that the constitutive activation of p38 MAP kinase did
not cause increased cell death of thymocytes in vivo. To
determine whether thymocytes from the MKK6(Glu) trans-
genic mice had a higher rate of proliferation, we examined
the fraction of cells synthesizing DNA by BrdU incorpora-
tion in vivo. As described previously, a large percentage of
thymocytes from control mice incorporated BrdU, indicat-
ing that they have undergone S phase transition during the
24-h labeling period (Fig. 4 F). The percentage of BrdU1
thymocytes in the MKK6(Glu) transgenic mice was com-
parable to the percentage found in control mice (Fig. 4 F),
indicating that the number of cells that had progressed
through S phase was similar. Together, these results indicate
that the accumulation of cells with .2N DNA content and
the corresponding reduction of the number of cells in G0/
G1 phase in the MKK6(Glu) transgenic mice were not
caused by an accelerated entry of G0/G1 cells into S phase,
suggesting that cell cycle progression could be partially in-
hibited at G2/M phase.
Therefore, the large CD81CD4lowCD251CD442 thy-
mocytes with .2N DNA content that accumulate in the
MKK6(Glu) transgenic mice could be mitotic cells, sug-
gesting that activation of p38 MAP kinase inhibited mitotic
progression of immature CD251CD442 thymocytes. In
correlation with this hypothesis, it has been shown that ac-
tivation of p38 MAP kinase, but not ERK or JNK, can ar-
rest the cell cycle in meiosis (M phase) in Xenopus embryos
(29). We examined whether activated MKK6 could inhibit
the progression of mitosis in immature thymocytes by Gi-
emsa staining, since propidium iodide staining does not dis-
criminate G2 from M phases. Most thymocytes (90–95%)
from negative littermate control mice were in interphase
(G0/G1, S, or G2), as indicated by the compact nuclei
present in these cells (Fig. 4 G). In contrast, a significant
proportion of the thymocytes from the MKK6(Glu) trans-
genic mice were in early/late prophase of mitosis, indicated
by the visualization of chromosomes and increased cell size
(Fig. 4 G). In addition, intracellular staining and flow cy-
tometry analysis showed that the level of cyclin A normally
expressed during mitosis was increased in thymocytes from
the MKK6(Glu) transgenic mice compared with control
thymocytes (Fig. 4 H). The level of cyclin-dependent ki-
nase inhibitor p27 levels was not affected (Fig. 4 H). These
results supported the hypothesis that the activation of p38
MAP kinase inhibited progression of mitosis in CD81CD4low
CD251CD442 thymocytes that progressively accumulate
in the thymus.
Inhibition of p38 MAP Kinase Restores Cell Cycle Progres-
sion and Differentiation of CD251CD442 Thymocytes. Dif-
ferentiation and proliferation are closely regulated during
the development of T cells in the thymus. Differentiation
of CD252CD441 thymocytes into CD251CD441 and
CD251CD442 thymocytes is associated with some prolif-
eration, but the principal expansion of cells occurs during
the differentiation of CD251CD442 thymocytes into CD252
CD442 thymocytes (for a review, see reference 1). How-
ever, it is unclear which of these processes, cell cycle pro-
gression or differentiation, initiates the transition between
two differentiation stages. Our results indicated that activa-
tion of p38 MAP kinase prevented cell cycle progression
and differentiation of CD251CD442 thymocytes. To ad-
dress which of these two biological functions is the cause of
the arrest of thymocyte development, we examined the ef-
fect of p38 MAP kinase inhibition on thymocytes from the
MKK6(Glu) transgenic mice. Thymocytes from adult MKK6
(Glu) transgenic mice were incubated in vitro with me-
dium alone or in the presence of different concentrations of
SB203580, a pyridinyl imidazol drug that selectively inhib-
its p38 MAP kinase (18). After 6 h, the nuclear morphol-
ogy of MKK6(Glu) thymocytes was examined by Giemsa
staining. As shown above, in the absence of the inhibitor a
large proportion of these cells remained in prophase (Fig.
5 A). However, after treatment with 1 mM SB203580, a
significant number of thymocytes in late anaphase/early te-
lophase was observed (Fig. 5 A). Cells in late telophase and
small cells in interphase were also detected upon incubation
with 5 mM SB203580 (Fig. 5 A). No SB203580 effect was
observed in control thymocytes (data not shown). Down-
regulation of cyclin A expression was also observed in the
MKK6(Glu) thymocytes treated with SB203580 (Fig. 5 B).
These results indicated that inhibition of p38 MAP kinase
is required for progression of mitosis in CD251CD442
thymocytes.
We examined whether the presence of SB203580 allowed
further differentiation of CD251CD442 thymocytes. No
significant differences in the expression of differentiation
cell markers were observed between 12 and 24 h of treat-
ment with SB203580 (data not shown). However, after 2 d
of treatment, immature CD251CD442 thymocytes differ-
entiated into DP thymocytes in a dose-dependent manner
(Fig. 5 C). The presence of SB203580 did not affect the
distribution of negative littermate control thymocytes (Fig.
5 C). The differentiation of CD81CD4low thymocytes from
the MKK6(Glu) transgenic mice into DP thymocytes in
the presence of SB203580 was associated with cell expan-
sion (Fig. 5 D). Therefore, inactivation of p38 MAP kinase
must occur for CD251CD442 thymocytes to progress
through mitosis, expand, and ultimately differentiate into
CD252CD442 and DP thymocytes.
Activation of the p38 MAP Kinase Pathway Is Important for
the Earliest Stages of Thymocyte Development. The presence
of high levels of p38 MAP kinase activity in immature
CD251CD442 thymocytes compared with the activity in
CD252CD442 thymocytes (Fig. 3 F) suggested that activa-
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ment of the CD251CD442 population. To address this hy-
pothesis, we generated transgenic mice that overexpress a
dominant-negative p38 MAP kinase (dn p38) in thymo-
cytes. The activating phosphorylation sites Thr180 and Tyr182
were replaced by Phe and Ala, respectively, in the dn p38
mutant (16). We have previously generated transgenic mice
that overexpress the dn p38 MAP kinase using the distal lck
promoter (30). No effect on thymic cellularity or the distri-
bution of thymic population was observed in these mice,
since the distal lck promoter does not drive transgene ex-
pression in DN thymocytes. Thus, we have generated new
transgenic mice in which dn p38 MAP kinase expression
was driven by the proximal lck promoter.
p38 MAP kinase activity was examined in thymocytes
from two different transgenic mouse lines. Decreased p38
MAP kinase activity was observed in thymocytes from mice
expressing the dn p38 MAP kinase (Fig. 6 A). Analysis of the
total number of thymocytes showed decreased thymic cel-
lularity in mice from two dn p38 transgenic lines (Fig. 6 B).
Although there were no significant differences in the per-
centages of DP and mature CD41 and CD81 populations,
the absolute number of each of these thymocyte popula-
tions was reduced in the dn p38 transgenic mice compared
with control mice (Fig. 6 C). These results suggested an im-
pairment in the very earliest stages of thymocyte develop-
ment that did not completely prevent further differentia-
tion but slowed the process. We also examined the presence
of the different DN thymocyte subsets defined by CD25
and CD44 expression in the dn p38 transgenic mice. No
significant reduction of the number of CD252CD442 was
observed in these mice. In contrast, the total number of
CD252CD441, CD251CD441, and CD251CD442 thymo-
cytes was reduced, supporting the hypothesis that activa-
tion of p38 MAP kinase is probably needed very early dur-
ing thymocyte development (Fig. 6 D).
To determine the regulation of p38 MAP kinase in the
different DN subsets, we examined the presence of acti-
vated p38 MAP kinase by intracellular staining and flow
cytometry using an antibody that specifically recognizes the
phosphorylated form of p38 MAP kinase. Competition ex-
Figure 5. Inactivation of p38
MAP kinase is required for
CD251CD442 cell cycle pro-
gression and differentiation. (A)
Inactivation of p38 MAP kinase
allows progression of mitosis in
CD251CD442 MKK6(Glu) thy-
mocytes. Thymocytes from the
MKK6(Glu) transgenic mice were
incubated in the presence of the
p38 MAP kinase inhibitor,
SB203580, at the indicated dose.
After 6 h, the cells were cytospun
and stained with Giemsa. Two or
three fields from the same slide
are presented. (B) Decreased cy-
clin A expression in MKK6(Glu)
thymocytes upon inactivation of
p38 MAP kinase. Total thy-
mocytes from the MKK6(Glu)
transgenic mice were treated in
the presence (red line) or absence
(black line) of SB203580 (1 mM)
for 12 h. Cyclin A expression was
examined by intracellular stain-
ing. (C) Inactivation of p38 MAP
kinase restores differentiation of
CD251CD442 MKK6(Glu) thy-
mocytes. Total thymocytes from
adult negative littermate control
(NLC) or MKK6(Glu) transgenic
(Tg1) mice were incubated for
2 d with the indicated concentra-
tions of the p38 MAP kinase in-
hibitor, SB203580. The recov-
ered cells were stained for CD4
and CD8 and analyzed by flow
cytometry. (D) Inhibition of p38
MAP kinase in MKK6(Glu) thy-
mocytes restores cell prolifera-
tion. Total thymocytes (106 cells)
were treated as described in C.
After 2 d, the number of live cells
was determined by trypan blue
staining.331 Diehl et al.
periments using a phospho-p38 peptide demonstrated the
specificity of this antibody (data not shown). In correlation
with the increase of p38 MAP kinase activity (threefold)
determined by the conventional immunocomplex kinase
assay (Fig. 3 F), intracellular staining and flow cytometry
analysis revealed increased levels (threefold) of activated
(phosphorylated) p38 MAP kinase in DN CD251CD442
thymocytes compared with DN CD252CD442 thymo-
cytes (Fig. 6 E). Interestingly, p38 MAP kinase activity was
dramatically augmented in the DN CD251CD441 popula-
tion compared with DN CD252CD441 thymocytes (Fig.
6 E), indicating that p38 MAP kinase is strictly regulated
during the differentiation of DN thymocytes.
Together, our results indicate that activation of the p38
MAP kinase pathway is important for differentiation and/or
survival of immature CD252CD441 thymocytes into CD251
CD441 and CD251CD442 thymocytes, but that inactiva-
tion of p38 MAP kinase is required to proceed from the
CD251CD442 to the CD252CD442 stage (Fig. 6 E).
Discussion
Reprogramming of gene expression patterns has been
implicated as a mechanism for the morphologic and func-
tional commitment of cells to specific lineages during the
development of T cells in the thymus. Transcription factors
and signaling pathways play critical roles in the control of
the differentiation, proliferation, and death of thymocytes.
Here, we have shown that the p38 MAP kinase pathway is
very strictly regulated during the early stages of thymocyte
development. The level of p38 MAP kinase activity is crit-
ical for both the differentiation and expansion of immature
thymocytes.
Using the MKK6(Glu) transgenic mice, we have shown
that persistent activation of p38 MAP kinase in thymocytes
in vivo results in a progressive increase of thymus size. The
enlarged thymus might theoretically be the result of a thy-
moma induced by the expression of activated MKK6. Sev-
eral lines of evidence presented in this study argue against
this possibility. First, splenomegaly and lymphadenopathy
Figure 6. Strict regulation of the p38 MAP ki-
nase pathway during immature thymocyte develop-
ment. (A) Expression of dn p38 in thymocytes in-
hibits endogenous p38 MAP kinase. Whole cell
extracts of freshly isolated thymocytes from negative
littermate control (NLC) and dn p38 transgenic
(TG1) mice from lines 2 and 10 were assayed for
p38 MAP kinase activity using the substrate GST-
ATF2. (B) Reduced total thymocyte number in the
dn p38 transgenic mice. Thymocyte numbers from
lines 2 and 10 of dn p38 transgenic mice are shown
as a percentage of the thymocyte number from neg-
ative littermate control mice. Values represent the
average percentage (n 5 4). (C) Reduced numbers
of DP, DN, and single CD41 and CD81 thy-
mocytes in the dn p38 transgenic mice (line 10).
Total thymocytes were isolated from control and dn
p38 transgenic mice, stained for CD4 and CD8, and
examined by flow cytometry. Values represent the
average percentage of thymocyte number in each
population versus the number of thymocytes of the
corresponding population in control mice (n 5 3).
(D) Reduced number of DN thymocyte popula-
tions in the dn p38 transgenic mice. Total thy-
mocytes were isolated from negative littermate con-
trol and dn p38 transgenic mice, stained for CD4, CD8, CD25, and CD44, and examined by flow cytometry. Values represent the average of the
absolute number of thymocytes in each DN subpopulation, based on the total number of thymocytes (n 5 3). (E) Activation and inactivation of p38
MAP kinase during earliest stage of thymocyte development. Total thymocytes from wild-type mice were stained for CD4, CD8, CD44, and CD25.
Cell surface staining was followed by intracellular staining for the active form of p38 MAP kinase using an FITC–antiphospho-p38 MAP kinase mAb.
Histograms (left) represent the presence of activated p38 MAP kinase in the different DN subpopulations (right) and DP cells. Vertical line represents the
negative control. Numbers express the mean fluorescence intensity of phospho-p38 MAP kinase positive cells. The results are representative of five inde-
pendent experiments.332 Activation of p38 MAP Kinase Arrests Thymocyte Development
are frequently associated with the development of thy-
moma. However, the spleen and lymph nodes from these
mice are dramatically reduced in size and cell number and
do not contain T cells. No metastases are found in other
organs of the MKK6(Glu) transgenic animals. Second, thy-
mocytes from the MKK6(Glu) transgenic mice do not ex-
hibit increased proliferation either in vivo or in vitro. Pro-
liferation of MKK6(Glu) thymocytes in vitro is observed
only when p38 MAP kinase is inactivated by the presence
of a specific inhibitor, SB203580. Third, despite the in-
creased size of the thymus, the total number of thymocytes
is reduced in embryos and young MKK6(Glu) transgenic
mice. Increased thymocyte cell number was observed only
after these mice reached 4–5 mo of age. The discrepancy
between the size of the thymus and the total number of
thymocytes can be explained by the difference in thy-
mocyte size. Flow cytometry and histological analysis (Figs.
3 A and 4 B) demonstrate that thymocytes from the MKK6
(Glu) transgenic mice are larger than thymocytes from con-
trol mice and would therefore occupy more space. Finally,
analysis of the TCR repertoire by examining different
TCR Vb (Vb5, Vb6, Vb8, and Vb11) expression demon-
strates that the thymocytes that accumulate in the MKK6
(Glu) transgenic mice do not represent a monoclonal popu-
lation (data not shown). Together, these observations make
it unlikely that the accumulation of thymocytes and progres-
sive enlargement of the thymus in the MKK6(Glu) trans-
genic mice are the result of development of a thymoma.
Instead, our studies demonstrate that the persistent acti-
vation of the p38 MAP kinase pathway arrests the differen-
tiation of immature thymocytes early in development. Sev-
eral lines of evidence confirm the immature phenotype of
the CD81CD4low population present in the thymus of the
MKK6(Glu) transgenic mice. First, the high level of HSA
and low level of CD69 and TCR-b expression detected on
thymocytes from the MKK6(Glu) transgenic mice are
characteristic of immature thymocytes (Fig. 3 D). Second,
MKK6(Glu) CD81CD4low thymocytes display the CD251
CD442 phenotype characteristic of a transient stage of im-
mature thymocytes before differentiation into DP thy-
mocytes (Fig. 3 C). Most importantly, we have demonstrated
that the arrest of thymocyte differentiation in the MKK6
(Glu) transgenic mice occurs during fetal development at
approximately E16–17 (Fig. 3 E). Finally, inhibition of p38
MAP kinase in vitro restores differentiation of the MKK6
(Glu) CD81CD4lowCD251CD442 thymocytes into DP thy-
mocytes (Fig. 5 C).
Recently, Sugawara et al. (8) have shown that the p38
MAP kinase inhibitor SB203580 inhibits deletion of DP
thymocytes by anti-CD3 mAb in fetal thymocyte develop-
ment organ culture (FTOC) in vitro. However, they also
show that the presence of SB203580 results in a decreased
percentage of DP thymocytes and increased percentage of
CD81, CD41, and DN thymocytes in FTOC (8). Thus, the
interpretation of these results is unclear. A differential effect
of SB203580 in stromal cells and thymocytes may explain
these apparently contradictory results. In the same study, it
was suggested that the expression of MKK6 induces nega-
tive selection of DP thymocytes. However, the presence of
the CD81CD4low population, increased percentage of DN
thymocytes, and absence of CD41 thymocytes in wild-type
MKK6 retrovirus-infected FTOC (8) do not support this
model. In contrast, these results suggest an inhibition of the
differentiation of immature fetal thymocytes into DP thy-
mocytes by the expression of wild-type MKK6. Thus, the
expression of wild-type MKK6 in FTOC  in vitro may
mimic the phenotype obtained in mice expressing constitu-
tively activated MKK6 in vivo.
The E and L subsets have been defined within the DN
CD251CD442 population in the adult thymus based on their
size, TCR-b expression, and cell cycle status (28). Differentia-
tion of thymocyte development is partially or completely in-
hibited at the CD251CD442 E stage (normal size thymocytes)
in mice deficient for components of the pre-TCR complex
(e.g., pre-Ta, TCR-b, CD3e, RAG, T cell factor [TCF]/
lymphoid enhancer-binding factor [LEF]–deficient mice) or
the pre-TCR signaling pathways (e.g., lck, ZAP-70, SH2 do-
main–containing leukocyte phosphoprotein of 76 kD [SLP-
76]–deficient mice) (1, 31–36). Thus, pre-TCR–mediated
signals appear to be critical for the progression from E to L
stage. In our study, we show that activation of the p38 MAP
kinase pathway does not prevent the expression of the TCR-b
and progression into the L stage. However, a persistent activa-
tion of p38 MAP kinase completely arrests the differentiation
of CD251CD442 L thymocytes into CD252CD442 and DP
thymocytes. Therefore, endogenous p38 MAP kinase must be
inactivated before differentiation to the CD252CD442 stage.
The analysis of p38 MAP kinase activity in these populations
confirms this model (Figs. 3 F and 6 E). The p38 MAP kinase
pathway therefore is the first signaling pathway that has been
described to play a critical role at the CD251CD442 L check-
point during thymocyte development.
The specific nuclear morphology (prophase), large size,
and low rate of proliferation in CD251CD442 thymocytes
from the MKK6(Glu) transgenic mice in vivo indicate that
MKK6(Glu) CD251CD442 thymocytes are arrested in mito-
sis. Moreover, progression of MKK6(Glu) thymocytes towards
telophase, cytokinesis, and G1 phases is restored upon inactiva-
tion of p38 MAP kinase in the presence of SB203580. There-
fore, activation of p38 MAP kinase in vivo prevents progres-
sion through the late phases of mitosis in CD251CD442
thymocytes. The study by Takenaka et al. (29) showing that
microinjection of activated p38 MAP kinase into blastomeres
of Xenopus embryos causes miotic arrest supports our results in
immature thymocytes. Recently, it has been proposed that ac-
tivation of the p38 MAP kinase pathway can inhibit progres-
sion of both G1 and mitosis in NIH-3T3 fibroblasts (37).
The inhibition of cell cycle progression of CD251CD442
thymocytes from the MKK6(Glu) transgenic mice appears
contradictory to the increased thymocyte number observed
in 5–6-mo-old MKK6(Glu) transgenic mice. Although
only a few cells (50–100/d) from the bone marrow repop-
ulate the thymus in control mice (38), these immature thy-
mocytes (predominantly CD252CD441 thymocytes) can
proliferate during their differentiation into CD251CD441
and CD251CD442 thymocytes. The major expansion of cell333 Diehl et al.
numbers appears to occur during the differentiation of
CD251CD442 into CD252CD442 thymocytes. The con-
tinuous entry of a new cohort of precursor cells into the
thymus and the differentiation and expansion of CD252
CD441 and CD251CD441 thymocytes can explain the slow
but progressive accumulation of thymocytes with time in
the MKK6(Glu) transgenic mice. Although the number of
fetal thymocytes in E15 MKK6(Glu) embryos was similar
to the number in age-matched control embryos, four- to
fivefold fewer thymocytes were found in E19 MKK6(Glu)
embryos compared with control embryos. Only 1.5–2-fold
fewer cells were found in 2–3-mo-old MKK6(Glu) trans-
genic mice, and 2–3-fold more thymocytes were found in
5–6-mo MKK6(Glu) mice compared with age-matched
control mice.
Proinflammatory cytokines (e.g., TNF-a and IL-1), he-
matopoietic factors (e.g., GM-CSF and IL-3), and environ-
mental stress can induce p38 MAP kinase activity in various
cell types (15–20). Interestingly, in correlation with the el-
evated p38 MAP kinase activity in the CD251CD441 thy-
mocytes, it has been shown that TNF-a and IL-1 produced
by stromal cells can stimulate the expression of surface CD25
on immature CD252CD441 thymocytes. Furthermore, these
two cytokines are required for the differentiation of imma-
ture fetal thymocytes into DP thymocytes (39). It is possi-
ble that p38 MAP kinase activity in immature thymocytes
may be regulated by stromal cell–derived cytokines.
Previous studies have demonstrated the involvement of
the p38 MAP kinase pathway in proliferation and cell
death. Our studies show the importance of the p38 MAP
kinase pathway in the control of differentiation and cell cy-
cle progression of CD251CD442 thymocytes in vivo. Pro-
liferation is closely associated with differentiation during
thymocyte development, and it remains unclear which of
these processes is the initial event in each developmental
step. We have demonstrated that the inhibition of p38 MAP
kinase in MKK6(Glu) thymocytes in vitro rapidly (several
hours) restores cell cycle progression, whereas a longer pe-
riod of time (24–48 h) is required to observe significant
changes on the cell surface phenotype. Therefore, we pro-
pose that inhibition of cell cycle progression by the p38
MAP kinase prevents further differentiation of immature
CD251CD442 thymocytes.
Our study demonstrates that p38 MAP kinase is strictly
regulated during the early stages of thymocyte develop-
ment. Although an initial activation of p38 MAP kinase ap-
pears to be important for thymic cellularity, persistent acti-
vation of this pathway completely blocks the generation of
T cells and results in T cell immunodeficiency. The regula-
tion of the p38 MAP kinase pathway is critical in thy-
mocyte development and generation of mature T cells.
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